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Abstract: A family history of atherosclerosis is independently associated with an increased incidence of cardiovascular 
events. The genetic factors underlying the importance of inheritance in atherosclerosis are starting to be understood. Ge-
netic variation, such as mutations or common polymorphisms has been shown to be involved in modulation of a range of 
risk factors, such as plasma lipoprotein levels, inflammation and vascular calcification. This review presents examples of 
present studies of the role of genetic polymorphism in atherosclerosis.  
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INTRODUCTION 
Atherosclerosis and the complications of this disease are 
the leading cause of disability and death in Western socie-
ties. The development of advanced atherosclerosis is a slow 
progressive process that starts in childhood and remains as-
ymptomatic for many decades, with complications such as 
myocardial infarction, stroke or peripheral ischaemia usually 
occurring in later life [1]. Recognised risk factors for the 
development of atherosclerosis include hypertension, diabe-
tes, dyslipidaemia, obesity, smoking, ageing and sedentary 
life style [2, 3]. Twin studies have suggested that the herita-
bility of coronary atherosclerosis based on fatal cardiac 
events is between 38 and 57% [4, 5]. Epidemiology studies 
suggest that a positive family history is independently asso-
ciated with the incidence of cardiovascular events [6]. Be-
sides major genetic determinants of traditional cardiovascu-
lar risk factors, such as those influencing the lipid profile, it 
is likely that a large number of additional genetic factors 
interact with environmental factors to determine overall car-
diovascular risk. Development of molecular biology tech-
niques has promoted identification of these candidate genes 
by using high-throughput technologies, such as genome-
wide scans. This review provides examples of advances in 
our understanding of the role of the genomic variations in 
atherosclerosis and candidate genes which have been related 
to atherosclerosis. 
CONSIDERATIONS IN GENOME STUDIES 
The methods used to examine genetic factors involved in 
chronic diseases such as atherosclerosis are evolving rapidly. 
Traditionally studies have centred on examining sub-popu- 
lation where the early onset of presentation, presence of mul-
tiple affected family members and mode of inheritance sug-
gest a very important role for genetics in the development of 
the disease. Using techniques such as affected-relative pair 
linkage  analysis  it  is possible to identify genomic regions   
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in which a single gene involved in the disease may be lo-
cated. In most chronic diseases however it is likely that mul-
tiple genes acting in concert under the influence of a range of 
environmental factors determine development of diseases, 
such as atherosclerosis. The identification of these genes has 
mainly followed a candidate gene approach. Based on under-
standing of the pathogenesis of atherosclerosis genes in-
volved in control lipid mobilisation, inflammation and endo-
thelial function for example have been examined for associa-
tion with atheroma presence or cardiovascular events. The 
selection of which sites of genetic variation within the genes 
to examine is complex depending on frequency of the varia-
tion, sample size or power, estimated functional effect and 
ability to predict other related genetic polymorphisms [7]. 
Over the last few years with the rapid advances in genotyp-
ing there has been the introduction of genome wide associa-
tion studies. This approach uses a screening rationale to ex-
amine up to 1 million allelic variations in large numbers of 
samples from cases and controls. The approach generates 
enormous data set which will ultimately enable analysis of 
epigenetic interaction and environmental responsive loci. At 
present our ability to analyse such data sets is relatively ru-
dimentary. 
In this review we will mainly discuss examples of the 
candidate gene approach since this has been the main tech-
nique applied. The selection of genes has been primarily 
based on our present understanding of the biology of athero-
sclerosis from in vitro, animal and pathological studies. An 
important issue in association studies is whether the correct 
allelic variation site in the gene of interest has been exam-
ined. Given the enormous number of variation even within a 
single gene it is usually not possible to examine every one. 
The size of cohort required for sufficient power to detect 
likely influence of a single genetic variation is very depend-
ant on the frequency of the minor allele within the popula-
tion being studied. For polymorphisms imparting a relative 
risk of 1.5 or less minor allele frequencies >5% are required 
for most achievable samples sizes [8]. Thus it is usual to 
target variations which are more common. Since a number of 
allelic variations are inherited together another important 
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selected those which are maximally linked to other common 
sequence changes. It has been demonstrated that the human 
genome can be organized into haplotype blocks i.e. regions 
of strong linkage disequilibrium (LD) separated by regions 
of low level LD [9-13]. The availability of detailed linkage 
information on different populations, such as that presented 
in HapMap (The International HapMap Consortium 2007 
[14]), allows researchers to select tagging single nucleotide 
polymorphisms and assesses different combinations of po-
lymorphisms or haplotypes. Another consideration in the 
selection of the allelic variations to be examined is its func-
tional effect. Databases, such as PANTHER (Protein ANaly-
sis THrough Evolutionary Relationships) gene ontology da-
tabase [15] can be utilised to provide estimates of the func-
tional effects of allelic variations. PANTHER uses subSPEC 
(substitution position-specific evolutionary conservation) 
score to predict the probability (Pdeleterious) that a given coding 
variant will cause a deleterious functional change, such that a 
subPSEC score of -3 corresponds to a Pdeleterious of 0.5 [16, 17]. 
A number of issues are raised in the selection of cases 
and controls for association studies, such as what criteria are 
used to define cases (e.g. history, documented events, imag-
ing), are controls from the same populations and has athero-
sclerosis been excluded thoroughly (history or imaging) [18]. 
GENETIC VARIANTS IN LIPOPROTEIN METABO-
LISM 
Aberrations in lipid handling are one of the fundamental 
mechanisms that have been linked to atherosclerosis, particu-
larly in patients presenting with positive family history and 
at younger age [19]. About three quarters of low density 
lipoprotein (LDL) in the blood stream is taken up by hepatic 
or peripheral cells via LDL receptors (LDLR) on the cell 
surface. These receptors recognize apolipoprotein B and 
apolipoprotein E with high affinity. In hepatocytes, the ab-
sorbed LDL is reused for lipoprotein synthesis and excess 
cholesterol is secreted into bile. In non-hepatic cells, the ab-
sorbed LDL supplies the cholesterol content essential for cell 
function. 
There is also reverse transport of excess cholesterol from 
the periphery back to the liver by high density lipoprotein 
(HDL) secreted by liver as nascent pre -HDL. Cholesterol 
efflux into mature HDL (HDL-C) is mediated by the ATP-
binding cassette (ABC) transporter family of membrane pro-
teins, especially ABCA1. HDL-C can then return to the liver 
via a hepatocyte scavenger receptor (SCARB1). In the liver, 
cholesterol can be stored within hepatocytes, converted into 
bile acids by the cytochrome P450 member CYP7A1 (7--
hydroxylase), or transported directly by ABCG5 and 
ABCG8 transporters. There is accumulated evidence that 
impaired homeostasis in these processes has a strong genetic 
background [20, 21].  
Low-Density Lipoprotein Receptor Gene (LDLR) 
Familial hypercholesterolemia (FH) is a monogenic auto-
somal codominant trait affecting 1 in 500 individuals in 
Caucasian populations [19] with an estimated world preva-
lence of about 0.2% [22]. FH is characterized by elevated 
plasma cholesterol bound to LDL (LDL-C) due to a defi-
ciency in LDLR activity on the cell surfaces [23]. 
LDLR is located on chromosome 19 [24] at 19p13.1-
p13.3 [23] and encodes a protein of 860 amino acids [25]. 
There are more than 800 different allelic variations in this 
gene described [26-30], which have been divided into 5 
classes according to the effect they have on LDLR function 
[26]. Class 1 mutations lead to an inability to produce im-
munoprecipitable protein (receptor-negative mutations), 
whereas classes 2-5 affect function of the receptor (receptor-
defective mutations). FH heterozygotes express half the 
normal number of functional LDLR on their cell surfaces 
leading to a twofold elevation in circulating LDL-C concen-
tration (300-500 mg/dL) associated with premature athero-
sclerosis development [19]. The rare FH homozygotes (1 in 
1,000,000) express only few or no functional receptors on 
their cell surfaces. These individuals have plasma LDL-C of 
600-1,200 mg/dL and may suffer fatal heart attacks before 
the age of 20 (reviewed in [19]). 
There is promising evidence that DNA polymorphisms 
within LDLR could be useful to monitor the inheritance of 
FH. Most association studies confirm the link between the 
restriction fragment length polymorphisms (RFLPs) in LDLR 
exon 12 or 13 and FH [31-34]. Two research groups reported 
strong linkage disequilibrium of two microsatellite markers 
(D19S394 and D19S221) to the most common LDLR muta-
tions (p.C152R, p.S265R, p.V408M and p.G528D), account-
ing for 20% and 60% of FH heterozygotes, respectively [35]; 
[36]. On the other hand, there is some consideration to gen-
eralize these polymorphisms as molecular markers for FH. 
At least, the data are based on individuals of different ethnic 
origin. The comparisons of haplotypes found in subjects of 
diverse ethnicity suggest heterogeneity among populations. 
For example, by using the LDLR HapMap genotype data 
[14], there were found distinct haplotype block patterns in 
four different populations (Fig. 1). To monitor the inheri-
tance of FH by using the common LDLR genetic variations, 
it is necessary to establish the panel of informative polymor-
phisms for any population of interest. 
Apolipoprotein B Gene (APOB) 
Human APOB is located on the short arm of chromosome 
2 [37] at 2p24-p23 [38] and codes for the main apolipopro-
tein of chylomicrons and LDL. The protein occurs in plasma 
in two main isoforms via a unique mRNA editing process: 
intestinal apoB-48 and hepatic apoB-100. ApoB-48 is identi-
cal to the N-terminal 48% of full-length apoB-100 [39, 40]. 
Two genetic disorders, familial hypobetalipoproteinemia 
(FHBL) and familial ligand-defective apoB-100 (FDB) are 
attributable to mutations in the APOB gene. FHBL is an 
autosomal dominant trait characterized by low plasma levels 
of total cholesterol (TC), LDL-C, and apoB. FDB is an auto-
somal dominant disorder accompanied by hypercholes-
terolemia and premature atherosclerosis [41]. Mutations 
within APOB cause the production of truncated proteins (be-
tween apoB-4.6 to apoB-89) and can be responsible for 
FHBL (reviewed in [42]). Defects in the C-terminus of the 
apoB LDLR-binding domain are accountable for FDB, 
which is clinically indistinguishable from FH [43]. 
The amino acid substitution p.R3500Q has been found  
to be strongly associated with hypercholesterolemia and 
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0.09% [47, 48]. The sequence variation p.R3531C impairs 
LDLR binding capacity up to 49% of normal and increases 
LDL-C concentration in plasma [49]. The p.R3480W substi-
tution leads to impaired binding to LDLR [50]. 
APOB is highly polymorphic gene with more than 80 al-
lelic variations within its entire sequence and other common 
genetic variants. For example, the APOB signal peptide ex-
hibits variability in length (24 or 27 amino acids) due to the 
insertion (ins allele) or deletion (del allele) of three codons 
[51-53]. The frequency of del allele is about 30% in Cauca-
sians [54] and has been associated with altered plasma total 
cholesterol and LDL-C levels in different ethnic groups [55-
60] but interestingly not with the risk of vascular diseases 
[54]. Thus variation at the apoB gene may act in pathogene-
sis of vascular diseases through mechanisms not directly 
related to effects on measured lipid traits. Linkage analysis 
of quantitative trait loci (QTL) associated with increased 
plasma levels of apoB protein provided evidence for chro-
mosomal segments at 1p21-31 and 17p11-q21 with LOD 
scores 2.2 and 3.7, respectively [61] in familial combined 
hyperlipidemia (FCHL) patients. While linkage peak on 
chromosome 1 fits to the dietary energy and nutrient intake 
linkage peak [62]; the peak at chromosome 17 corelates to 
QTL for type 2 diabetes [63] and blood pressure variation 
and hypertension [64, 65]; all risk factors for cardiovascular 
diseases. 
Several restriction fragment length polymorphisms 
(RFLP) and variable number of tandem repeats (VNTR) po-
lymorphisms have also been described within APOB coding 
as well as 3’-untranslated region (3’-UTR), [66, 67]. Studies 
examining the association of these common genetic varia-
tions in APOB with atherosclerosis have led to inconsistent 
findings [68-72]. 
Apolipoprotein E Gene (APOE) 
APOE is a key protein of the lipid-transporting system 
[73, 74], regulating serum cholesterol [75], and participating 
in formation of high density lipoprotein (HDL) particles 
[76]. Hepatic parenchymal cells mediate production of all 
peripheral APOE [73]. APOE-containing particles are rap-
idly removed from the circulation by binding to LDLR or 
LDLR-like protein receptor (LRP)-mediated endocytosis in 
the liver [77-79]. 
APOE is mapped to chromosome 19 at 19q13.2 [80]; 
[81] where it is linked to apolipoprotein C1 and C2 [82]. 
APOE has four exons and three introns [83]. The gene is 
polymorphic with three major alleles (APOE2, APOE3, and 
APOE4) translating into three protein isoforms 2, 3, and 4 
[84-86]. They differ from each other only by single amino 
acid substitutions at residues 112 and 158 [87, 88]. The most 
common variant is 3 (~78% in Caucasians; [89]) and carries 
cysteine and arginine at position 112 and 158, respectively. 
Minor molecular change has profound pathological conse-
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Fig. (1). Complex correlation structure to the HapMap genotype data at LDLR gene locus (19p13.2) in four populations. 
(a) Utah residents with ancestry from northern and western Europe, (b) Han Chinese in Beijing (China), (c) Japanese in Tokyo (Japan), (d) 
Yoruba in Ibadan (Nigeria). 32    Current Genomics, 2008, Vol. 9, No. 1  Biros et al. 
suggests that the influence of other APOE genetic variants is 
small by comparison to its major alleles (E2, E3, and E4). 
ATP Binding Cassette Transporter 1 Gene (ABCA1) 
ABCA1 functions as a cholesterol efflux pump in the 
apolipoprotein mediated cellular lipid removal pathway [97]. 
Specifically, ABCA1 mediates the transport of cholesterol 
from cells to lipid-poor apolipoprotein (apo) A-I, the major 
HDL protein (reviewed in [98]); [99]. Mutations within the 
ABCA1 gene explained the molecular basis of Tangier dis-
ease, the autosomal codominant trait characterized by re-
duced serum HDL (<5mg/dL) and subsequent premature 
coronary atherosclerosis [100-102]. Disease causative muta-
tions (e.g. g.3283_3284delTC in exon 22; [103]) have led to 
the hypothesis that common polymorphisms in ABCA1 con-
trol serum lipoprotein levels as a risk factor of
 atherosclero-
sis in the general population. ABCA1 is mapped to chromo-
some 9 at 9q31.1 [104] and displays multiple common varia-
tions within its sequence. Some of these polymorphisms cor-
relate to circulating lipid or lipoprotein levels [105-110]. 
Among major lipid-relevant genes, ABCA1 haplotypes 
influence HDL and LDL/HDL ratio by only 10% and 4%, 
respectively [111]. Thus, it is not surprising that other stud-
ies by Zwarts et al. [108] and Tregouet et al. [112] (ECTIM - 
Etude Cas-T´emoins de l’Infarctus du Myocarde study) re-
ported that ABCA1 polymorphisms are associated with the 
frequency and severity of coronary events independent of 
changes in the circulating lipoprotein levels. Promoter as 
well as 5’-UTR variants have been associated with multiple 
increases in coronary events and severity of coronary artery 
disease. 
CYP7A1 Gene 
This gene codes for a member of the cytochrome P450 
superfamily of enzymes and is located on chromosome 8 at 
8q11-q12 [113]. CYP7A1 is one of the critical genes playing 
a role in the classical pathway of cholesterol conversion into 
bile acids (reviewed in [114]). Genetic variations in CYP7A1 
have been extensively studied and associated with hypercho-
lesterolaemia in some [115-118] but not all studies [119, 
120]. When association was reported, it consistently related 
to the promoter region of the gene. There is not any common 
non-synonymous polymorphism within its coding sequences, 
except the exon 3 c.762A>G with the estimated frequency of 
heterozygosity at about 0.006. While it is not known any 
functional variants of this polymorphism, it can not be ex-
cluded that there is another close-linked gene with common 
polymorphisms that is involved in the control of plasma lip-
ids. Gene layout around the CYP7A1 locus indicates for syn-
tenin (SDCBP), the gene coding for protein with pleiotropic 
functions, including the cell signalling and lipid metabolism.  
ABCG5/ABCG8 Locus 
ATP-binding cassette sub-family G members 5 and 8 
(ABCG5 and ABCG8) are tandemly arranged in a head-to-
head orientation on chromosome 2p21 [121, 122]. The ABC 
transporters, ABCG5 (sterolin-1) and ABCG8 (sterolin-2) 
function in trafficking of all sterols, including cholesterol 
[123]. Multiple mutations in either ABCG5 or ABCG8 may 
result in sitosterolaemia [124-127]; a rare autosomal reces-
sive trait characterized by increased intestinal absorption and 
decreased biliary excretion of sterols. Subjects with this dis-
order develop premature coronary atherosclerosis [128]. Ge-
netic polymorphisms within the sitosterolaemia locus explain 
inter-individual differences in sterol metabolism and plasma 
sitosterol [129]. Polymorphic variants p.Q604E (ABCG5), 
p.D19H and p.T400K (ABCG8) have been associated with 
plasma plant sterols and lipid levels in normocholesterolae-
mic individuals or mildly hypercholesterolaemic patients 
[130-133]. Variant p.M429V (ABCG8) was linked to higher 
cholesterol absorption efficiency in hypercholesterolaemic 
patients [134]. Pandit et al. [135] published a detailed haplo-
type map of the sitosterolaemia locus. They found ABCG8 
gene to be more polymorphic than ABCG5. Some of allelic 
variations were in strong LD and very unique to different 
ethnic groups. A polymorphism in ABCG8 has been linked 
to the response of serum LDL cholesterol to atorvastatin 
therapy [136]. This is an example of how genetic variability 
can influence the outcome of treatment of atherosclerosis not 
just its development. 
SCARB1 Gene 
Scavenger receptors (SRs) are receptors for modified 
forms of lipoproteins including oxidized and acetylated LDL 
(ox-LDL and ac-LDL), lipopolysaccharides (LPS) of Gram-
negative bacteria, and other poly-anionic ligands [137, 138]. 
They are divided into eight classes (A-H) and the majority of 
them are expressed on the surface of antigen presenting cells 
– APC [139]. Several informative sequence variations have 
been found within the member of the scavenger receptors 
gene family B, scavenger receptor class B type 1 gene 
(SCARB1). This gene spans approximately 75kb on chromo-
some 12 at 12q24.31 [140, 141]. Allelic variations within the 
coding sequence of the SCARB1 gene have been found in 
exons 1 and 8 [142, 143]. Both polymorphisms exhibit anti-
atherogenic properties and the phenotype seems to vary with 
gender. While exon 1 variant was associated with increased 
HDL-C and lower LDL-C in men, exon 8 variation was 
linked to lower LDL-C concentrations in women [142, 144]. 
Exon 8 allelic variation has no impact on amino acid se-
quence and is believed to be in linkage disequilibrium with 
other functional mutations within SCARB1 or adjacent loci at 
12q24 chromosomal region. Other putative susceptibility 
genes in this region include TP53 regulated inhibitor of 
apoptosis 1 (TRIAP1) and ATP-binding cassette sub-family 
B member 9 (ABCB9). 
Other Loci Controlling Lipid Metabolism 
Several genome-wide linkage scans have been performed 
to detect quantitative trait loci (QTLs) regulating lipid or 
lipoprotein metabolism. As the most significant results, these 
studies identified linkage between 19p13 (LOD score 3.00) 
and plasma cholesterol concentration [145]. Chromosomes 
16q23.1-24.2 (LOD score 3.73), [146], 12q14.1 (LOD score 
4.06), [147] and 15q21 (LOD score 4.77), [148] were linked 
to HDL-C. While sequences at 1q43, 11q23.2, 15q25.1 and 
19q13.32 (LOD scores 2.50, 3.22, 3.11 and 3.59), [147] and 
1p33-35 (LOD score 3.60), [149] were linked with LDL-C. 
Chromosomal segments at 15q12-q13.1 (LOD score 3.88), 
[150] and 7q36 (LOD score 2.98), [151] linked to TG. Genetic Variation and Atherosclerosis  Current Genomics, 2008, Vol. 9, No. 1    33 
Several prominent candidate genes residing within these 
linkage regions are shown in Table 1. Among them, muta-
tions in proprotein convertase subtilisin/kexin type 9 
(PCSK9) gene and low density lipoprotein receptor adaptor 
protein (LDLRAP1) gene (encoding a protein required for 
clathrin-mediated internalization of the LDL receptor by 
liver cells) have already been reported to affect LDLR path-
way. Recent data indicates that about ten PCSK9 mutations 
are associated with hypercholesterolemic or hypocholes-
terolemic phenotype [152-156]. Recessive null mutations 
within LDLRAP1 were observed to co-segregate with hyper-
cholesterolemia [157] that is particularly common in Sar-
dinia [158], presumably because of the founder effect. 
BEYOND LIPOPROTEINS 
An abundance of data has shown the relationship be-
tween circulating lipoprotein variables and risk of cardiovas-
cular events. On the other hand, half of all coronary events 
occur in subjects with below-average cholesterol levels [3]. 
In this section we discuss some other genes that have been 
associated with atherosclerosis. Inflammation plays an im-
portant role in the development and complications of athero-
sclerosis (reviewed in [2]); [159]. Monocyte-macrophage 
recruitment appears to be particularly important. This proc-
ess engages multiple genes. As an example we highlight 
transforming growth factor beta 1 (TGFB1) and scavenger 
receptors or toll like receptor family (TLR). Calcification is 
another important feature of advanced atherosclerosis. We 
also highlight two genes linked to calcification i.e. secreted 
phosphoprotein 1 (SPP1), also known as osteopontin (OPN) 
and tumor necrosis factor receptor superfamily member 11B 
(TNFRSF11B), also known as osteoprotegerin (OPG). Ma-
trix metalloproteinases have been identified in many impor-
tant stages in atheroma formation including inflammation 
and plaque rupture [160]. 
Table 1.  Candidate Genes within Chromosomal Linkage Regions Involved in Lipoprotein Metabolism 
Ref.  Subjects  Ethnicity  Linkage Site  LOD  Related Phenotype  Candidate Gene(s) 
[147] Obese  families  Caucasian  12q14.1  4.06  HDL-C  SOAT2, APOF, CYP27B1 
[224]  Population based study  Caucasian  5p13.1  3.64  HDL-C   
[146]  Population based study  Mexican Americans  16q23.1-24.2  3.73  HDL-C  LCAT 
[225] Familial  combined  hyperlipidemia Caucasian  3p14  3.00  HDL-C  ACOX2 
[148]  Population based study  Caucasian  15q21  4.77  HDL-C  LIPC 
[226]  Low HDL-C families  Caucasian  8q23  4.70  HDL-C   
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[149]  Healthy children  African Americans  1p33-35  3.60  LDL-C  PCSK9, LDLRAP1, CYP4A11 







ACAT1, APOA1, APOC3, ACAD8 
[228] Hypertriglyceridemic  families  Caucasian  15q21-q24 2.56  TG  LIPC 
[151] Obese  families  Caucasian  7q36  2.98 TG  INSIG1, ABCF2, FABP5L3 
[150]  Type 2 diabetes families  Caucasian  15q12-q13.1 3.88  TG  LIPC 
[229]  Population based study  Caucasian  7q32.3-qter  2.50  TG/HDL-C ratio  ABCF2 
[145]  Type 2 diabetes families  Pima Indians  19p13  3.00  TC  INSR, C3 
SOAT2 sterol O-acyltransferase 2; APOF apolipoprotein F; CYP27B1 cytochrome P450, subfamily XXVIIB, polypeptide 1; LCAT lecithin: cholesterol acyltransferase; PLAGL1 
pleomorphic adenoma gene-like 1; ACOX2 acyl-CoA oxidase 2, LIPC lipase, hepatic; ABCB10 ATP-binding cassette, subfamily B, member 10; GGPS1 geranylgeranyl diphosphate 
synthase 1; ACAT1 acetyl-CoA acetyltransferase 1; APOA1 apolipoprotein A-I; APOC3 apolipoprotein C-III; CYP11A cytochrome P450, subfamily XIA, polypeptide 1; LRP3 low 
density lipoprotein receptor-related protein 3; APOE apolipoprotein E; LIPE lipase, hormone-sensitive; APOC1 apolipoprotein C-I; PPARG peroxisome proliferator-activated recep-
tor-gamma; APOB apolipoprotein B; ABCG5 ATP-binding cassette, subfamily G, member 5; ABCG8 ATP-binding cassette, subfamily G, member 8; LDLR low density lipoprotein 
receptor; PCSK9 proprotein convertase, subtilisin/kexin-type, 9; LDLRAP1 low density lipoprotein receptor adaptor protein 1; CYP4A11 cytochrome P450, subfamily IVA, polypep-
tide 11; FABP1 fatty acid-binding protein 1; ABCC8 ATP-binding cassette, subfamily C, member 8; LRP4 low density lipoprotein receptor-related protein 4; ACAD8 acyl-CoA 
dehydrogenase family, member 8; INSIG1 insulin-induced GENE 1; ABCF2 ATP-binding cassette sub-family F member 2; FABP5L3 fatty acid binding protein 5-LIKE 3; INSR 
insulin receptor; C3 complement component 3. 34    Current Genomics, 2008, Vol. 9, No. 1  Biros et al. 
Transforming Growth Factor Beta 1 Gene (TGFB1) 
This gene is located on chromosome 19 at 19q13.1-q13.3 
[161, 162] and codes for a pleiotropic cytokine, which regu-
lates proliferation and differentiation of a wide variety of cell 
types [163]. The quantitative production of TGFB1 differs 
amongst individuals due to genetic polymorphism with esti-
mated heritability of approximately 0.54 [164]. Increased 
plasma levels of the cytokine are associated with the T-allele 
of the promoter g.509C>T sequence variation due to loss of 
negative regulation by the complex of transcription factors 
AP1, JUND, and c-FOS [165]. This complex can bind 
TGF1 only when wild-type C-allele is present. The deregu-
lation of this pathway has been suggested to play a role in 
mediating predisposition to various diseases, including athe-
rosclerosis [166-169]. For example a polymorphism in 
TGF1 has been associated with stroke [170]. 
Toll Like Receptors (TLR) and Scavenger Receptors (SR)  
Toll like receptor family contains the pattern recognition 
receptors (PRRs) of various pathogen-associated molecular 
patterns (PAMPS), [171]. There are more than ten human 
members of the family specialized in recognition of both 
endogenous and exogenous ligands [172-174]; (reviewed in 
[175]). Ligation of TLR4 that signals through myeloid dif-
ferentiation primary response protein MyD88-dependent 
pathway towards the pro-inflammatory nuclear factor B 
(NF-B) signalling cascade (reviewed in [176]) has been 
proposed to play an important role in the initiation and pro-
gression of atherosclerosis (reviewed in [177]). TLR4 has 
been demonstrated in macrophages within atherosclerotic 
plaques and shown to be up-regulated by ox-LDL [178]. 
Hoebe et al. [179] demonstrated that TLRs and macrophage 
type A scavenger receptor (SR-A) can functionally cooperate 
in macrophage-bacteria interactions and signalling. Recent 
work by Seimon et al. [180] has revealed that macrophages 
in the atherosclerotic plaques apoptose when TLR4 and SR-A 
are activated at the same time. SR-A ligands trigger macro-
phage apoptosis via  endoplasmic reticulum (ER)-stressed 
pathway by redirection of TLR4 signalling from pro-survival 
to pro-apoptotic. This combination of signalling can lead to 
plaque rupture and arterial thrombosis. 
Given the role of TLRs and SRs in cell signalling, identi-
fication and functional characterization of polymorphisms in 
genes coding for these receptors may influences important 
stages of the development and complications of atheroscle-
rosis. Common, co-segregating missense coding allelic 
variations in the TLR4 gene on chromosome 9q32-q33 [181] 
encode the p.D299G, and p.T399I substitutions that blunt 
receptor signalling [182]. A link between hypo-responsive 
TLR4 and susceptibility to cardiovascular events has been 
assessed in multiple association studies with variable obser-
vations. Ameziane et al. [183], Edfeldt et al. [184] and Hol-
loway et al. [185] reported the association of TLR4 allelic 
variation with myocardial infarction; however other studies 
could not confirm these findings [186, 187]. These inconsis-
tencies may be clarified by simultaneous examination of 
sequence variations with other polymorphic associates of the 
TLR4 physiological pathway. 
The class A scavenger receptors are responsible for ap-
proximately 75% of the degradation of ox-LDL and ac-LDL 
[188]. Matsumoto et al. and [189] Emi et al. [190] mapped 
the SR-A gene on chromosome 8 to 8p22. Besides several 
germ-line mutations identified within this gene [191], there 
are more than 200 polymorphisms mapped to the entire ge-
nomic region of the SR-A  including three putative non-
synonymous sequence variations in exon 4 at amino acid 
position 105 (rs13306549), exon 5 at amino acid position 
269 (rs13306543) and exon 6 at amino acid position 275 
(rs3747531). 
Secreted Phosphoprotein Gene (SPP1) 
SPP1 is an acidic glycophosphoprotein normally found in 
mineralized tissues acting as an inhibitor of apatite crystal 
growth [192]. SPP1 has been demonstrated at sites of calcifi-
cation in atherosclerotic plaques and in calcified aortic 
valves [193-195]. SPP1 has been implicated in a variety of 
mechanisms important in atherosclerosis including prolifera-
tion and migration of endothelial cells, macrophages, and 
vascular smooth muscle cells [196, 197]. 
The gene coding for SPP1 was assigned to chromosome 
4q21-q25 [198]. There are more than sixty allelic variations 
at the SPP1 locus, including six non-synonymous variants 
coding for an amino acid change. Recently, Taylor et al. 
[199] in the CARDIA study and Brenner et al. [200] re-
ported an SPP1 allele specific association with coronary ar-
tery calcification and stroke, respectively. 
Tumor Necrosis Factor Receptor Superfamily Member 
11b Gene (TNFRSF11B) 
TNFRSF11B gene was mapped to chromosome 8q24 
[201]. TNFRSF11B belongs to the tumour necrosis factor 
(TNF) receptor super-family and acts as a decoy receptor of 
the receptor activator of the NF-B ligand (RANKL) that is a 
strong inducer of osteoclast differentiation acting through its 
receptor activator of NF-B (RANK) receptor [202]. 
Recent studies on TNFRSF11B tissue expression, serum 
levels, or gene polymorphisms also suggest an important role 
of the RANKL/RANK/TNFRSF11B cytokine system in 
atherosclerosis and vascular calcification. While TNFRSF- 
11B is detected in both normal and atherosclerotic tissue, 
RANKL/RANK is expressed only in calcified arteries [203]. 
Moreover, TNFRSF11B is more abundant in symptomatic 
than in asymptomatic carotid plaques, suggesting a role in 
the plaque instability [204]. 
Recent study of four promoter polymorphisms (g.163A>G, 
g.209G>A, g.245T>G and g.950T>C) in the promoter region 
of the TNFRSF11B gene in a Korean cohort failed to identify 
any association with coronary artery disease (CAD) or aortic 
calcification [205]. On the other hand, previous haplotype 
analysis of the g.950T>C and g.G1181G>C (exon 1) showed 
significant association with CAD in Caucasian men [206] 
suggesting ethnic differences. An increased risk of CAD was 
reported in carriers of at least one C allele of both polymor-
phisms. The C allele at position 950 also correlated with 
serum TNFRSF11B levels. 
Matrix Metalloproteinases (MMPs) 
MMPs, a family of diverse enzymes consisting of 24 
zinc-dependent endopeptidases, process various components Genetic Variation and Atherosclerosis  Current Genomics, 2008, Vol. 9, No. 1    35 
of the extra-cellular matrix and cell surface proteins (re-
viewed in [207]). Altered MMP activities have been impli-
cated in a variety of pathological processes, including athe-
rosclerosis [208]. Several members of the MMP family have 
functional polymorphisms that have been assessed for asso-
ciation to atherosclerosis, e.g. MMP1, MMP3, and MMP9. 
For these genes, promoter polymorphisms have been linked 
to increased risk of carotid artery stenosis [209, 210]. 
Other Candidate Genes 
A genome-wide scan by Lange et al. [211] revealed two 
distinct linkage peaks at chromosomal regions 6p21.3 (LOD 
score 2.22) and 10q21.3 (LOD score 3.24), which may har-
bour genes associated with coronary atherosclerosis. Sug-
gested candidate genes within these regions include collagen 
type XI 2 (COL11A2) and allograft inflammatory factor 1 
(AIF1) on chromosome 6, plus collagen type XIII 1 
(COL13A1) and bone morphogenetic protein receptor type 
1A (BMPR1A) on chromosome 10. BMPR1A was found 
overexpressed in asymmetric dimethylarginine (ADMA) 
conditioned coronary artery endothelial cells under patho-
physiological concentrations [212]. ADMA is a naturally 
occurring component of plasma that inhibits nitric oxide syn-
thesis and was linked to major adverse cardiovascular events 
or death [213].  
Association of coronary artery disease with polymor-
phism on chromosome 6 has been confirmed by another 
study reporting a linkage peak between 6p12–p22 [214]. The 
investigators suggested vascular endothelial growth factor 
(VEGF) localized at 6p12 (LOD score 2.21) as a promising 
candidate gene. A number of other studies have suggested 
genomic sites linked with coronary atherosclerosis and/or 
myocardial infarction [215-223]. Helgadottir et al. [220] in 
their linkage study of 713 cardiac patients reported linkage 
peak at 12q22 coding for leukotriene A4 hydrolase (LTA4H) 
as a candidate gene. The authors proposed the role of leukot-
rienes in mediating individual susceptibility to myocardial 
infarction. Table 2 provides examples of putative genes re-
siding within these loci and their amino acid substitution 
causing by non-synonymous SNPs. We scored these 
polymorphisms to predict their functional significance 
(subPSEC value) by using the PANTHER’s coding SNP 
analysis tool [17]. The substitutions T600S (LTA4H) and 
R443C (BMPR1A) showed the highest subPSEC values of -
2.62 and -8.29 with probability of deleterious effect (Pdeleteri-
ous) of 0.41 and 0.99, respectively; suggesting these variants 
for further studies in relation to cardiovascular diseases. 
CONCLUSION 
Atherosclerosis is a complex disorder depending on an 
interaction between genotype and environment. The relative 
contribution of genes and environment varies from one pa-
tient to another. There is no unifying genetic pattern that is 
associated with atherosclerosis. Mendelian disorders, such as 
FH or sitosterolaemia explain only a small part of disease 
risk indicating the involvement of complex non-Mendelian 
traits and their combined effects. While some individuals 
suffer from hereditary impaired lipoprotein homeostasis, for 
others, chronic inflammation or vascular calcification may 
be the prevalent cause of their increased susceptibility. Large 
studies examining different populations are on going and 
will shed further light on the importance of different genes 
for different presentations of atherosclerosis. 
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